𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The role of high-dose imatinib in the management of patients with gastrointestinal stromal tumor

✍ Scribed by Alessandro Gronchi; Jean-Yves Blay; Jonathan C. Trent

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
202 KB
Volume
116
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Adjuvant and neoadjuvant imatinib therap
Adjuvant and neoadjuvant imatinib therapy: Current role in the management of gastrointestinal stromal tumors
✍ Burton L. Eisenberg; Jonathan C. Trent πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 French βš– 212 KB

## Abstract Although surgery remains the mainstay for the treatment of primary gastrointestinal stromal tumors (GIST), a significant number of patients experience disease recurrence within 5 years of surgery. The emergence of imatinib therapy for the treatment of patients with advanced GIST has off

Expression of Bcl-2 in gastrointestinal
Expression of Bcl-2 in gastrointestinal stromal tumors : Correlation with progression-free survival in 81 patients treated with imatinib mesylate
✍ Dejka M. Steinert; Mauricio Oyarzo; Xuemei Wang; Haesun Choi; Peter F. Thall; L. πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 224 KB πŸ‘ 1 views

## Abstract ## BACKGROUND The natural history of gastrointestinal stromal tumor (GIST) has been revolutionized by imatinib mesylate (imatinib) therapy. Before imatinib, Bcl‐2 expression in GIST was associated with a worse prognosis or added no additional prognostic value. To the authors' knowledge